-DOCSTART- -X- O
Zika -X- _ B-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
ZIKV -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
an -X- _ O
emerging -X- _ O
mosquito-borne -X- _ O
flavivirus -X- _ O
that -X- _ O
has -X- _ O
spread -X- _ O
to -X- _ O
more -X- _ O
than -X- _ O
70 -X- _ O
countries -X- _ O
worldwide -X- _ O
since -X- _ O
2015. -X- _ O
Despite -X- _ O
active -X- _ O
research -X- _ O
, -X- _ O
there -X- _ O
are -X- _ O
currently -X- _ O
no -X- _ O
licensed -X- _ O
vaccines -X- _ O
or -X- _ O
therapeutics. -X- _ O
We -X- _ O
have -X- _ O
previously -X- _ O
reported -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
various -X- _ O
adenoviral -X- _ O
vectored -X- _ O
vaccine -X- _ O
candidates -X- _ O
( -X- _ O
ChAdOx1 -X- _ B-Patient
ZIKV -X- _ I-Patient
) -X- _ O
with -X- _ O
the -X- _ O
ability -X- _ O
to -X- _ O
stimulate -X- _ O
effective -X- _ O
immunity -X- _ O
in -X- _ O
mice -X- _ O
and -X- _ O
provide -X- _ O
protection -X- _ O
upon -X- _ O
a -X- _ O
ZIKV -X- _ O
challenge -X- _ O
model -X- _ O
, -X- _ O
using -X- _ O
a -X- _ O
non-adjuvanted -X- _ O
single -X- _ O
vaccination -X- _ O
approach. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
constructed -X- _ O
various -X- _ B-Intervention
modified -X- _ I-Intervention
vaccinia -X- _ I-Intervention
Ankara -X- _ I-Intervention
( -X- _ I-Intervention
MVA -X- _ I-Intervention
) -X- _ I-Intervention
viruses -X- _ I-Intervention
to -X- _ I-Intervention
express -X- _ I-Intervention
the -X- _ I-Intervention
ZIKV -X- _ I-Intervention
Envelope -X- _ I-Intervention
( -X- _ I-Intervention
E -X- _ I-Intervention
) -X- _ I-Intervention
with -X- _ I-Intervention
modifications -X- _ I-Intervention
on -X- _ I-Intervention
the -X- _ I-Intervention
precursor -X- _ I-Intervention
membrane -X- _ I-Intervention
( -X- _ I-Intervention
prM -X- _ I-Intervention
) -X- _ I-Intervention
or -X- _ I-Intervention
on -X- _ I-Intervention
the -X- _ I-Intervention
C-terminus -X- _ I-Intervention
envelope -X- _ I-Intervention
transmembrane -X- _ I-Intervention
domain -X- _ I-Intervention
( -X- _ I-Intervention
TM -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
similar -X- _ O
to -X- _ O
our -X- _ O
ChAdOx1 -X- _ O
vaccine -X- _ O
candidates. -X- _ O
MVA-ZIKV -X- _ B-Patient
vaccine -X- _ I-Patient
candidates -X- _ I-Patient
were -X- _ O
evaluated -X- _ O
as -X- _ O
a -X- _ O
non-adjuvanted -X- _ O
single -X- _ O
vaccination -X- _ O
regimen -X- _ O
against -X- _ O
a -X- _ O
ZIKV -X- _ O
Brazilian -X- _ O
isolate -X- _ O
, -X- _ O
using -X- _ O
viraemia -X- _ O
as -X- _ O
the -X- _ O
correlate -X- _ O
of -X- _ O
protection. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
report -X- _ O
the -X- _ O
induction -X- _ O
of -X- _ O
a -X- _ O
modest -X- _ B-Outcome
level -X- _ I-Outcome
of -X- _ I-Outcome
anti-ZIKV -X- _ I-Outcome
E -X- _ I-Outcome
antibodies -X- _ I-Outcome
by -X- _ O
all -X- _ O
MVA -X- _ O
vectored -X- _ O
vaccines -X- _ O
and -X- _ O
sub-optimal -X- _ B-Outcome
efficacy -X- _ I-Outcome
in -X- _ O
a -X- _ O
ZIKV -X- _ O
challenge -X- _ O
model. -X- _ O
Our -X- _ O
results -X- _ O
indicate -X- _ O
the -X- _ O
requirement -X- _ O
of -X- _ O
additional -X- _ O
strategies -X- _ O
when -X- _ O
using -X- _ O
MVA-ZIKV -X- _ O
vaccines -X- _ O
to -X- _ O
afford -X- _ O
sterile -X- _ O
protection -X- _ O
upon -X- _ O
a -X- _ O
non-adjuvanted -X- _ O
and -X- _ O
single -X- _ O
vaccination -X- _ O
regime -X- _ O
. -X- _ O

